Skip to content
Pharma Observatory a Scientist.com platform

Organization (Other)

UNICANCER

ClinicalTrials.gov lists UNICANCER as lead sponsor of 219 trials. It has 353 active development programs and 104 approved assets.

Other
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

26 0 1994 2027

Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.

2026 is partial: 24 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 26 in 2026 and about 22 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (5 to 20), forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored. 1 trial is registered to start in 2027 or later.

This page covers UNICANCER: 219 lead-sponsored trials and 0 legal-entity registrations.

Get the UNICANCER report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Disease areas (94)

Shown in this order: most trials first.

Disease areas
Disease area Trials
Breast Neoplasms 79
Colorectal Neoplasms 38
Head and Neck Neoplasms 29
Neoplasm Metastasis 29
Carcinoma, Squamous Cell 20

Trials by start year as sponsor or collaborator (32)

Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.

Show the table of trials by start year as sponsor or collaborator
Trials by start year as sponsor or collaborator
Year Trials started
2026 (partial year) 24
2025 19
2024 10
2023 7
2022 9
2021 6
2020 10
2019 15
2018 14
2017 17

Prediction, not a registry value: median of 36 months from start to primary completion across 46 trials still running at the 2026-10-09 snapshot; registered median of 56 months across 143 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

Active development programs (353)

Shown in this order: max phase, then active trials.

Active development programs
Drug Disease area Max phase Trials
OXALIPLATIN Colorectal Neoplasms Phase 3 10
FOLFOX regimen Colorectal Neoplasms Phase 3 4
AG chemotherapy Neoplasm Metastasis Phase 3 3
Androgen Deprivation Therapy Prostatic Neoplasms Phase 3 2
Capecitabine Tablets Breast Neoplasms Phase 3 2

Approved assets (104)

Shown in this order: max phase first.

Approved assets
Drug Trials
FLUOROURACIL 23
OXALIPLATIN 17
CYCLOPHOSPHAMIDE 16
DOCETAXEL 14
CISPLATIN 14

Sponsor delivery record (1)

Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.

Sponsor delivery record
Enrollment Timeline
43% hit target (n=95) 39% on time (n=77)

Journals published in (133)

Shown in this order: most published in first.

Journals published in
Journal Publications
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 44
Annals of oncology : official journal of the European Society for Medical Oncology 29
European journal of cancer (Oxford, England : 1990) 28
The Lancet. Oncology 28
The New England journal of medicine 16

Organization relationships (10)

Shown in this order: most evidence first.

Organization relationships
Related organization Relationship Evidence
European Organisation for Research and Treatment of Cancer - EORTC Co sponsors trial with 5
Fondation ARC Co sponsors trial with 2
Groupement Interrégional de Recherche Clinique et d'Innovation Co sponsors trial with 1
Biobanque de Picardie Co sponsors trial with 1
University Hospital, Bordeaux Co sponsors trial with 1

Latest dated events (267)

Shown in this order: newest first.

Latest dated events
Date Event Source
2027-01-02 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-12-31 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-12-01 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-10 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-09-25 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))

Biomarker capability evidence (1,012)

Shown in this order: tier desc, then gene symbol.

Biomarker capability evidence
Gene Role Evidence
ACP3 Trial sponsor Named in trial inclusion criteria
AFP Trial sponsor Named in trial inclusion criteria
AFP Trial collaborator Named in trial inclusion criteria
ALB Trial sponsor Named in trial inclusion criteria
ALB Trial sponsor Named in trial inclusion criteria

Not on this page

Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.